Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 41kWORD 18k
14 February 2019
P-000861-19
Question for written answer P-000861-19
to the Commission
Rule 130
Frédérique Ries (ALDE)

 Subject:  Follow-up to European Parliament resolution on Lyme disease
 Answer in writing 

On 15 November 2018, MEPs adopted the first resolution on Lyme disease, an underdiagnosed ‘silent epidemic’ spread by ticks, which affects about one million people in Europe.

An official report published by the US Department of Health and Human Services in November 2018 recognises the problems associated with serological testing and acknowledges that earlier and more reliable methods of diagnosis are needed.

Parliament’s main recommendations include:
Commission-established monitoring programmes and improved cooperation between Member States with a view to standardising diagnostic tests and treatments;
Calling on Member States to draft compulsory reports to map the spread of the Borrelia bacterium and to establish individual measures to prevent and control ticks.
2. Can the Commission inform us whether the funds — which amount to about EUR 16 million so far — allocated to Lyme borreliosis research through the ANTIDotE, ID-Lyme and Lymediatex projects are yielding conclusive results and give hope for an improvement in patients’ lives?
3. Does the Commission intend to fund new research protocols on Lyme disease?

1. Are these recommendations being followed up in practice?

Original language of question: FR 
Last updated: 20 February 2019Legal notice